State-of-the-art therapy for severe sepsis and multisystem organ dysfunction

American Journal of Surgery

Volumn 186, Issue 5 SUPPL. 1, 2003, Pages 23-30

  Awad, Samir S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFECTIVE AGENT; INSULIN; STEROID;

BLEEDING; BREATHING DISORDER; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; ENTERIC FEEDING; FIBRINOLYSIS; GLUCOSE METABOLISM; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERMETABOLISM; IMMUNOPATHOLOGY; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG DISEASE; METABOLIC DISORDER; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESUSCITATION; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0348109444     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2003.10.004     Document Type: Conference Paper

References (55)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States analysis of incidence, outcome, and associated costs of care . Crit Care Med. 29:2001;1303-1310.
2. Baue A. MOF/MODS, SIRS an update . Shock. 6:(suppl):1996;S1-S5.
3. Beal A.L., Cerra F.B. Multiple organ failure syndrome in the 1990s systemic inflammatory response and organ dysfunction . JAMA. 271:1994;226-233.
4. Bone R.C., Grozin C.J., Balk R.A. Sepsis a new hypothesis for pathogenesis of the disease process . Chest. 112:1997;235-243.
5. Sauaia A., Moore F.A., Moore E.E., et al. Early predictors of postinjury multiple organ failure. Arch Surg. 129:1994;39-45.
6. Angus D.C., Birmingham M.C., Balk R.A., et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis a randomized controlled trial. E5 Study Investigators . JAMA. 283:2000;1723-1730.
7. van der Poll T., Butler H.R., ten Cate H., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 322:1990;1622-1627.
8. van Deventer S.J., Buller H.R., ten Cate J.W., et al. Experimental endotoxin in humans analysis of cytokine release and coagulation, fibrinolytic and complement pathways . Blood. 76:1990;2520-2526.
9. Carvalho A.C., Freeman N.J. How coagulation defects alter outcome in sepsis survival may depend on reversing procoagulant conditions . J Crit Illn. 9:1994;51-75.
10. Hinshaw L.B. Sepsis/septic shock participation of the microcirculation: an abbreviated review . Crit Care Med. 24:1996;1072-1078.
11. Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome a randomized, controlled, double-blind, multicenter clinical trial . JAMA. 273:1995;934-941.
12. Abraham E., Glauser M.P., Butler T., et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock a randomized controlled multicenter trial . JAMA. 277:1997;1531-1538.
13. Natanson C., Esposito C.J., Banks S.M. The sirens' songs of confirmatory sepsis trials selection bias and sampling error . Crit Care Med. 26:1998;1927-1931.
14. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
15. Bone R.C. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis . Crit Care Med. 20:1992;724-726.
16. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 31:2003;1250-1256.
17. Rangel-Frausto M.S., Pittet D., Costigan M., et al. The natural history of the systemic inflammatory response syndrome (SIRS) a prospective study . JAMA. 273:1995;117-123.
18. St. John R.C., Dorinsky P.M. An overview of multiple organ dysfunction syndrome. J Lab Clin Med. 124:1994;478-483.
19. Fry D.E., Pearlstein L., Fulton R.L., Polk H.C. Jr. Multiple system organ failure the role of uncontrolled infection . Arch Surg. 115:1980;136-140.
20. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. Prognosis in acute organ-system failure. Ann Surg. 202:1985;685-693.
21. Demling R., Lalonde C., Saldinger P., Knox J. Multiple organ dysfunction in the surgical patient pathophysiology, prevention, and treatment . Curr Probl Surg. 30:1993;345-414.
22. Cipolle M.D., Pasquale M.D., Cerra F.B. Secondary organ dysfunction from clinical perspectives to molecular mediators . Crit Care Clin. 9:1993;261-298.
23. Yao Y.M., Redl H., Bahrami S., Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res. 47:1998;201-210.
24. Levi M., ten Cate H., van der Poll T., van Deventer S.J. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA. 270:1993;975-979.
25. Ferrante A., Kowanko I.C., Bates E.J. Mechanisms of host tissue damage by cytokine-activated neutrophils. Immunol Ser. 57:1992;499-521.
26. Toledo-Pereyra L.H., Suzuki S. Neutrophils, cytokines, and adhesion molecules in hepatic ischemia and reperfusion injury. J Am Coll Surg. 179:1994;758-762.
27. Strieter R.M., Lynch J.P., Basha M.A., et al. Host responses in mediating sepsis and adult respiratory distress syndrome. Semin Respir Infect. 5:1990;233-247.
28. Fisher C.J. Jr, Dhainaut J.F., Opal S.M., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome results from a randomized, double-blind, placebo-controlled trial . JAMA. 271:1994;1836-1843.
29. Kidokoro A., Iba T., Fukunaga M., Yagi Y. Alterations in coagulation and fibrinolysis during sepsis. Shock. 5:1996;223-228.
30. Vervloet M.G., Thijs L.G., Hack C.E. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 24:1998;33-44.
31. Lorente J.A., Carcia-Frade L.J., Landin L., et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 103:1993;1532-1536.
32. Fisher C.J., Yan S.B. Protein C levels as prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 28:(suppl):2000;S49-S56.
33. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults a multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis . JAMA. 274:1995;968-974.
34. Awad SS, Bartlett RH. Multiple organ dysfunction syndrome: pathogenesis, prevention, and management. In: Baker RJ, Fischer JE, eds. Mastery of Surgery.
35. Hirvela E. Advances in the management of acute respiratory distress syndrome. Arch Surg. 135:2000;126-134.
36. Frankenfield D.C., Reynolds H.N., Wiles C.E., et al. Urea removal during continuous hemodiafiltration. Crit Care Med. 22:1994;407-412.
37. Eliahou H.E., Ben-David A., Blau A. Recovery can be enhanced in acute renal failure of multisystem organ failure. Contrib Nephrol. 106:1994;59-62.
38. Wardle E.N. Acute renal failure and multiorgan failure. Nephron. 66:1994;380-385.
39. Cumming A.D. Sepsis and acute renal failure. Ren Fail. 16:1994;169-178.
40. Demling R.H., Lalonde C., Ikegami K. Physiologic support of the septic patient. Surg Clin North Am. 74:1994;637-658.
41. Moore F.A. The role of the gastrointestinal tract in postinjury multiple organ failure. Am J Surg. 178:1999;449-453.
42. Shah B.R., Hux J.E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 26:2003;510-513.
43. Van Den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 345:2001;1359-1367.
44. Mileski W.J., Winn R.K., Harlan J.M., Rice C.L. Transient inhibition of neutrophil adherence with the anti-CD18 monoclonal antibody 60.3 does not increase mortality rates in abdominal sepsis. Surgery. 109:1991;497-501.
45. Taylor F.B. Jr, Chang A., Ruf W., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 33:1991;127-134.
46. Dhainaut J.F., Marin N., Cariou A. Perspectives in anti-inflammatory therapies in sepsis. Eichacker P.Q., Pugin J. Evolving Concepts in Sepsis and Septic Shock. 2001;145-161 Kluwer Academic Publishers, Boston.
47. Bernard G. Severe sepsis. Am J Surg. 184:(suppl):2002;S3-S4.
48. Dhainaut J.F. Introduction rationale for using drotrecogin alfa (activated) in patients with severe sepsis . Am J Surg. 184:(suppl):2002;S5-S10.
49. Sollet J.P., Garber G.E. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. Am J Surg. 184:(suppl):2002;S11-S18.
50. Morris P.E., Light R.B., Garber G.E. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated). Am J Surg. 184:(suppl):2002;S19-S24.
51. Schein R.M., Kinasewitz G.T. Risk-benefit analysis for drotrecogin alfa (activated). Am J Surg. 184:(suppl):2002;S25-S38.
52. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 288:2002;862-871.
53. Heinzelmann M., Scott M., Lam T. Factors predisposing to bacterial invasion and infection. Am J Surg. 183:2002;179-190.
54. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 345:2001;1368-13677.
55. Charlebois E.D., Bangsberg D.R., Moss N.J., et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis. 34:2002;425-433.